Research and Clinical Trials

Title  
ASCO TAPUR: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Brief Description  
To describe the anti-tumor activity (efficacy) and toxicity (safety) of commercially available, targeted anti-cancer drugs used for treatment of patients with advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma with a genomic variant known (i) to be a target of an FDA-approved anti-cancer drug or (ii) to predict sensitivity to an FDA-approved anti-cancer drug.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Other Female Genital
Status  
OPEN
Start Date  
03/21/2016
IRB Number  
00014171
Principal Investigator  
Kim, Edward Sanghyun
Contact Name  
Kelly D Bumgarner

For More Information, Contact  Kelly  D, Bumgarner
Phone:  704-403-2520 Fax:    
Email:  Kelly.Bumgarner@carolinashealthcare.org
Address:100 Medical Park Drive Suite 110 Concord, NC 28025
Close